Uromigos-Bladder Cancer
Advertisement
Dr. Mark Tyson from Mayo Clinic joins the podcast to discuss the high CR rate seen in cohort C of the BOND-003 trial.
Dr. Neal Shore joins the show to discuss exciting data from the CREST trial.
Dr. Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer.
Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer.
Brian and Tom discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.
Dr. Gopa Iyer of Memorial Sloan Kettering Cancer Center joins the show to discuss his initial results.
Dr. Matt Galsky joins the show to discuss pathological complete response rates from the NIAGARA trial.
Dr. Xinan Sheng joins the podcast to discuss the update of this trial and impressive pCR rates.
Romain Banchereau, PhD, joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in UC.
Dr. Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer from 2024.
Jonathan Rosenberg joins the podcast to discuss new updates on the phase 3 TROPiCS-04 study.
Dr. Bishoy Faltas of Weill Cornell Medicine joins us to discuss his work on extrachromosomal DNA in bladder cancer.
Christopher Cutie from J and J joins the show to discuss the SUNRISE bladder program.
Drs. Maite Bourlon, Elena Castro and Cristina Suarez cover the UC topics discussed on day 1 of Uromigos Live 2024.
Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024.
Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024.
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Fresh off the Presidential session address, Tom discusses his data with Petros commenting.
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotin + pembrolizumab in bladder cancer.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.